Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mark Mangurian"'
Autor:
Shanthi Marur, Mark Mangurian, Melissa Pozotrigo, Shika Marur, Corey Wise, Hiywete Solomon, Nicole Hartung, Haya Abu-Seir, Meera Ravindranathan, Rory Makielski, Adam Leikensohn, William Early, Andrew D Norden, Andrew Toler, Laura Bobolts
Publikováno v:
Transplantation and Cellular Therapy. 29:S193-S194
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e50819c6190453f78e2bff755b9f2f41
https://doi.org/10.1016/s2666-6367(23)00320-2
https://doi.org/10.1016/s2666-6367(23)00320-2
Autor:
Andrew Toler, Laura R. Bobolts, Mark Mangurian, Melissa Pozotrigo, Corey Wise, Hiywete Solomon, Nicole Hartung, Rory Makielski, Shika Marur, Meera Ravindranathan, Shanthi Marur
Publikováno v:
Cancer Research. 83:P4-01
Background: Trastuzumab deruxtecan (T-DXd) improves outcomes in HER2-positive metastatic breast cancer (MBC) patients, including patients with previously treated stable brain metastases (BMs). Our objective was to examine the characteristics of HER2-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1504256fa88beb2cb54a7810f1a2acea
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-36
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-36
Autor:
Laura R. Bobolts, Mark Mangurian, Shanthi Marur, Corey Wise, Melissa Pozotrigo, Hiywete Solomon, Nicole Hartung, Meera Ravindranathan, Rory Makielski, Shika Marur, Andrew Toler
Publikováno v:
Cancer Research. 83:P4-01
Background: Trastuzumab deruxtecan (T-DXd) improves outcomes in HER2-positive, and recently in HER2-low (IHC 1+ or IHC 2+/ISH-) previously treated metastatic breast cancer (MBC) patients. OncoHealth is a digital health care company that leverages man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebf3630274f80612f3f195e50a530fc1
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-40
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-40